Feasibility and population exposure of 5‐fluorouracil using therapeutic drug monitoring (PREDICT‐5FU): A multicentre clinical trial
TDM dosing is feasible and increases the proportion of patients reaching target AUC. Findings are relevant across all cancers treated with 5FU, and particularly for DPYD variant allele carriers receiving upfront dose reductions.
Authors
- Jennifer Martin (ORCID: https://orcid.org/0000-0002-8614-0199)
- Marliese Alexander (ORCID: https://orcid.org/0000-0001-5782-7912)
- Nicholas Zdenkowski (ORCID: https://orcid.org/0000-0001-8738-8463)
- S. Sandun M. Silva (ORCID: https://orcid.org/0000-0003-4672-981X)
- Howard Gurney (ORCID: https://orcid.org/0000-0003-0217-5261)
- Stephen P. Ackland (ORCID: https://orcid.org/0000-0001-5303-0017)
- Sarah Glewis (ORCID: https://orcid.org/0000-0002-7764-5427)
- Ian Olver (ORCID: https://orcid.org/0000-0001-5478-1576)
- Peter Galettis (ORCID: https://orcid.org/0000-0002-6785-2529)
- Madawa Jayawardana (ORCID: https://orcid.org/0000-0002-6990-1785)
- Craig Kukard
- Jeanne Tie (ORCID: https://orcid.org/0000-0001-9244-2057)
- Michael Michael (ORCID: https://orcid.org/0000-0002-0593-2662)
Institutions
- The University of Melbourne (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Peter MacCallum Cancer Centre (AU)
- The University of Adelaide (AU)
- University of Newcastle Australia (AU)
- Macquarie University (AU)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-02-23
- DOI
- https://doi.org/10.1002/bcp.70006
- Citations
- 4
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Cancer Council NSW